Why is "semaglutide sodium" a red flag on a compounded label?

The pharmacy is accredited and I have verified that on the accreditor register.

I have read the primary source rather than the summary, which has left me with more questions.

I understand the headline. I do not understand the footnotes, and the footnotes look important.

What would I need in addition before this supported a decision?

Potency variation between compounders is a manufacturing-control question rather than an integrity question, and it is the predictable consequence of preparing a potent peptide by hand at small scale.

The salt-form point: the statutory pathway for compounding a copy of an approved drug during a shortage applies to the same active moiety as the approved product. A preparation described as a salt form — "semaglutide sodium", "semaglutide acetate" — is describing a different chemical entity from the approved base, and the description is usually there to construct an argument that it is not a copy. Whatever the legal merits, it means what is in the vial is not what was studied.

Denials come in two flavours and it is worth identifying which you have. A criteria denial means the submission did not evidence something the criteria require, and it is fixed by supplying the evidence. A formulary exclusion means the plan does not cover the drug at any level for any indication, and no amount of clinical documentation changes it — the route there is a formulary exception request or an employer-level appeal.

Accreditation by the Pharmacy Compounding Accreditation Board or by ACHC is voluntary and verifiable, and verification is a matter of checking the accreditor’s register rather than accepting a logo on a website.

Keep every document. The appeal you might need in six months is built from records you have to have kept now.

The salt-versus-base issue is worth understanding precisely because it is a genuine regulatory tell rather than a technicality.

Features of a defensible telehealth intake: a real history including contraindications and family history, a recorded weight and height rather than a self-attested figure, baseline laboratory work or a documented reason for its absence, a named prescriber you can identify and verify, a titration plan, and a mechanism for reporting adverse events that reaches a clinician. A checkbox intake that issues a prescription in four minutes has none of these.

503A and 503B differ in what they are permitted to do and what they must demonstrate. A 503A pharmacy compounds against individual prescriptions, is exempt from current good manufacturing practice requirements, and is regulated primarily at state level with USP chapter compliance as the operative standard. A 503B outsourcing facility registers federally, must comply with cGMP, may prepare without patient-specific prescriptions, and is subject to FDA inspection. The practical consequence is that a 503B preparation carries release testing and a 503A preparation generally does not.

One qualification: this is a description of process, not legal or medical advice. Where a decision has legal consequences, it deserves someone whose professional obligation is to you.

Model twelve months, not one. The fee structures are designed to be compared monthly.

edited 4 Oct 2024 by tyndall_haze — removed a claim I could not source

The underlying point is that model the cost across the whole route, including the parts that are not the drug: consultation fees, laboratory monitoring, shipping, and the tests you will pay for yourself.

Whether a telehealth prescription can be filled at a retail pharmacy depends on the prescription and the jurisdiction rather than on the modality: a prescription for a licensed product from a prescriber licensed in the patient’s jurisdiction is generally fillable anywhere that stocks it. A prescription written to a specific compounding pharmacy for a preparation only that pharmacy makes is not portable, and that non-portability is sometimes the commercial point.

External review of health-plan denials in the United States operates under the Affordable Care Act’s appeal provisions and, for employer self-funded plans, under ERISA; the practical significance is that an independent reviewer applies the plan’s own criteria without the plan’s involvement.

The limitation of cost modelling is that it assumes a stable price environment, and the price environment in this category has been anything but stable.

Ask for the written criteria before you submit. Everything else in the process is easier once you have them.

edited 5 Sept 2024 by ruaidhri_o_shea — updated for the 2026 guidance change

A defensible telehealth encounter has identifiable features, and the absence of those features is the most useful signal available to a prospective patient.

A beyond-use date for a compounded multi-dose preparation is set under USP chapter provisions on the basis of microbiological risk category and, where available, supporting stability data. In practice most beyond-use dates in this space are default values from the risk-category table rather than the output of a stability study, and the two should not be read as equivalent claims.

The caveat is jurisdictional. Almost everything in this area is specific to a country and often to a sub-national jurisdiction, and a confident answer that does not name a jurisdiction should be treated as describing somewhere else.

If the intake did not ask about contraindications, that tells you what kind of service it is.